and is a member of its audit committee and its finance and investment committee. Earlier in her career, Ms. Capps was a Senior Audit Accounting Professional at Ernst & Young, LLP.
Ms. Capps is a California Certified Public Accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Ms. Capps holds a Bachelors degree in Business Administration/Accounting from San Diego
State University.
We believe Ms. Capps is qualified to serve on our board of directors because of her exceptionally strong skill set
consisting of corporate finance, accounting, operations, investor relations, capital markets and strategic business development.
Ciara Kennedy, Ph.D. has served on our board of directors since March 2020. Since December 2016, Dr. Kennedy has served as
President, Chief Executive Officer and director of Amplyx Pharmaceuticals, and previously served as the companys Chief Operating Officer beginning in October 2015. Amplyx is a clinical-stage company developing innovative drug therapies for
debilitating and life-threatening diseases in patients with compromised immune systems. Prior to Amplyx, she served as Chief Operating Officer at Lumena Pharmaceuticals, until the companys acquisition by Shire Pharmaceuticals, and then
continued as Vice President, Head of Cholestatic Liver Disease at Shire post acquisition. Previously, Dr. Kennedy held several positions at Cypress Bioscience where she played a key role in the companys FDA approval and launch of Savella® for fibromyalgia, and also held several positions in program and alliance management at Biogen Idec where she managed multiple development projects spanning the drug discovery and development
continuum. She is a founder of Reneo Pharmaceuticals and Mirum Pharmaceuticals, and also serves as a director of privately held Aristea Therapeutics. Dr. Kennedy received her doctorate at the Queens University of Belfast, Northern
Ireland, her Master of Business Administration from the Rady School of Management at University of California, San Diego, and her Bachelor of Science from University College Cork, Ireland.
We believe Dr. Kennedy is qualified to serve on our board of directors because of her experience as an investor in biopharmaceutical and
life sciences companies, her educational background, and her leadership in the medical and life science industries.
Iain McGill
has served on our board of directors since August 2016. Since June 2019, Mr. McGill has served as Chief Executive Officer and as a member of the board of directors of Quell Therapeutics, a cell and gene therapy company in the immune
dysregulations field. From July 2010 to June 2019, Mr. McGill served in various positions at Jazz Pharmaceuticals plc, an international biopharmaceutical company, and, prior to its acquisition by Jazz Pharmaceuticals in 2012, EUSA Pharma, a
specialty pharmaceutical company, including as Senior Vice President, Europe and Rest of World from March 2015 to June 2019, as Head of EUSA Pharma and Senior Vice President, Jazz Pharmaceuticals from March 2014 to March 2015, and as Chief
Commercial Officer, EUSA Pharma, from June 2012 to March 2014. From 2006 to 2009, Mr. McGill served as Vice President and Global Business Manager for Transplantation and Immunology at Wyeth, a pharmaceutical company acquired by Pfizer Inc.
Mr. McGill holds a Bachelor of Science degree in Biochemistry from the University of London.
We believe Mr. McGill is qualified
to serve on our board of directors because of his leadership experience in the biotechnology and pharmaceutical industries.
Continuing Directors
James B. Breitmeyer, M.D., Ph.D. has served on our board of directors since June 2018. Since September 2015,
Dr. Breitmeyer has served as President, Chief Executive Officer and director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotechnology company. He has been a director of Zogenix, Inc., a pharmaceutical company, since March 2014,
and was their acting Chief Medical Officer from August 2012 to February 2013. Previously, Dr. Breitmeyer served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in
Denmark, from February 2013 to July 2015. He previously served as the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., a pharmaceutical company, from August 2006 to August 2012, and the Chief Medical
-10-